Oak Ridge Investments LLC reduced its position in shares of AtriCure, Inc. (NASDAQ:ATRC – Get Rating) by 35.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,479 shares of the medical device company’s stock after selling 36,089 shares during the period. Oak Ridge Investments LLC’s holdings in AtriCure were worth $4,234,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Pinebridge Investments L.P. acquired a new position in shares of AtriCure during the fourth quarter worth $56,000. First Horizon Advisors Inc. increased its holdings in shares of AtriCure by 80.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,496 shares of the medical device company’s stock worth $103,000 after buying an additional 667 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of AtriCure by 10.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,341 shares of the medical device company’s stock worth $162,000 after buying an additional 215 shares in the last quarter. Lindbrook Capital LLC acquired a new position in shares of AtriCure during the fourth quarter worth $168,000. Finally, Captrust Financial Advisors increased its holdings in shares of AtriCure by 5.6% during the third quarter. Captrust Financial Advisors now owns 2,544 shares of the medical device company’s stock worth $177,000 after buying an additional 135 shares in the last quarter. Institutional investors and hedge funds own 95.36% of the company’s stock.
Several brokerages have recently issued reports on ATRC. BTIG Research lowered their price target on shares of AtriCure from $94.00 to $75.00 and set a “buy” rating for the company in a report on Friday, June 24th. Needham & Company LLC reduced their price objective on shares of AtriCure from $67.00 to $55.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. Finally, StockNews.com raised shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.33.
AtriCure (NASDAQ:ATRC – Get Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The medical device company reported ($0.33) EPS for the quarter, meeting analysts’ consensus estimates of ($0.33). The business had revenue of $74.58 million for the quarter, compared to analysts’ expectations of $71.17 million. AtriCure had a net margin of 17.93% and a negative return on equity of 11.66%. The business’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.32) earnings per share. As a group, equities research analysts anticipate that AtriCure, Inc. will post -1.09 EPS for the current year.
In other news, insider Tonya Austin sold 3,203 shares of the stock in a transaction dated Friday, May 13th. The shares were sold at an average price of $42.69, for a total transaction of $136,736.07. Following the transaction, the insider now owns 17,621 shares of the company’s stock, valued at approximately $752,240.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.80% of the stock is owned by corporate insiders.
AtriCure Profile (Get Rating)
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.
- Get a free copy of the StockNews.com research report on AtriCure (ATRC)
- Using MarketBeat Market Data Tools To Find Strong Stocks in a Bear Market
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.